NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova^®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024.

“Prime Day has been a highly productive event for NovaBay in past years and conveniently falls during National Dry Eye Awareness Month when there is increasing focus on this chronic condition that affects about 25 million Americans,” said Justin Hall, NovaBay CEO. “The discounts allow our loyal customers to stock up on the Avenova products they regularly use while also enticing them to try other products in our dry eye regimen that may provide additional relief from this often-multifactorial condition."

“The Prime Day event also benefits NovaBay by prompting new users to try our high-quality Avenova products,” he added. “We have found these new users often return as repeat customers, thus helping to build our business. In fact, last week we announced that the number of Avenova Subscribe & Save customers on Amazon, which is our largest sales channel, increased 123% since the beginning of 2022.”

NovaBay offers a full portfolio of scientifically developed products for each step of the standard at-home dry eye treatment regimen. These include Avenova Lid & Lash Solution, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. NovaBay also offers Avenova product bundles specifically designed to provide easy, affordable and effective solutions for individualized needs.

About NovaBay Pharmaceuticals, Inc.

NovaBay’s leading product Avenova^® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., it is clinically proven in-vitro to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. In addition to the Avenova OTC product line, NovaBay offers the Avenova Allograft, an amniotic tissue prescription-only product available through eyecare professionals nationwide.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "preliminary," "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding NovaBay’s participation in Amazon’s Prime Day. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-Q/K filings with the SEC, as may be amended from time to time, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBay’s Progress

Like us on Facebook

Follow us on X

Connect with NovaBay on LinkedIn

Visit NovaBay's Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email sales@avenova.com

Avenova.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716903103/en/